Manuscripts
Showing 1600 manuscripts.
Markers of maternal bone and renal toxicity through 50 weeks postpartum: IMPAACT 2010 (VESTED) Trial
Citation
Gaerolwe Masheto, Sean S Brummel, Lauren Ziemba, John Shepherd, Tapiwa Mbengeranwa, Laarni Igawa, Anne Coletti, Dorinda Mukura, Lindie Rossouw, Gerhard Theron, Chelsea Krotje, Patrick Jean-Philippe, Nahida Chakhtoura, Haseena Cassim, Sisinyana Ruth Mathiba, Joel Maena, William Murtaugh, Lee Fairlie, Judith Currier, Risa Hoffman, Lameck Chinula, Paul E. Sax, Lynda Stranix-Chibanda, IMPAACT 2010/VESTED study team and investigators. Markers of maternal bone and renal toxicity through 50 weeks postpartum: IMPAACT 2010 (VESTED) Trial. Journal of Acquired Immune Deficiency Syndromes. 2024 Oct 01; 97(2):172-179. PMID: 39250651; PMCID: PMC11384307.Year
2024
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
IMPAACT 2010
Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial
Citation
Sufia Dadabhai, Victoria B. Chou, Mauricio Pinilla, Lameck Chinula, Maxensia Owor, Avy Violari, Dhayendre Moodley, Lynda Stranix-Chibanda, Taguma Allen Matubu, Gift Tafadzwa Chareka, Gerhard Theron, Aarti Avinash Kinikar, Mwangelwa Mubiana-Mbewe, Lee Fairlie, Raziya Bobat, Blandina Theophil Mmbaga, Patricia M. Flynn, Taha E. Taha, Katie S. McCarthy, Renee Browning, Lynne M. Mofenson, Sean S. Brummel, Mary Glenn Fowler, PROMISE 1077BF/FF Team. Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial. AIDS. 2024 Mar 04; PMID: 38427596.Year
2024
Journal
AIDS
Impact of HIV drug resistance mutations detected in women prior to antiretroviral therapy with efavirenz + tenofovir + lamivudine (or emtricitabine)
Citation
Ceejay L. Boyce, Tatiana Sils, Ross S. Milne, Jackson J. Wallner, Samantha R. Hardy, Daisy Ko, Annie Wong-On-Wing, Malia Mackey, Nikki Higa, Ingrid A. Beck, Sheila M. Styrchak, Patricia DeMarrais, Camlin Tierney, Mary G. Fowler, Lisa M. Frenkel, PROMISE Study Team. Impact of HIV drug resistance mutations detected in women prior to antiretroviral therapy with efavirenz + tenofovir + lamivudine (or emtricitabine). Lancet HIV. 2024 Jul 15;Year
2024
Journal
Lancet HIV
Lamivudine Dosing for Preterm Infants Exposed to HIV: a Population Pharmacokinetic Modelling and Simulation Study
Citation
Adrie Bekker, Edmund V. Capparelli, Mark Mirochnick, Diana F. Clarke, Mark F Cotton, Roger Shapiro, Katie McCarthy, Jack Moye, Avy Violari, Kulkanya Chokephaibulkit, Elaine Abrams, Martina Penazzato, Ted Ruel, Tim R. Cressey. Lamivudine Dosing for Preterm Infants Exposed to HIV: a Population Pharmacokinetic Modelling and Simulation Study. Journal of Antimicrobial Chemotherapy. 2024 Oct 01; 79(10):2570-2574. PMID: 39092932; PMCID: PMC11441998.Year
2024
Journal
Journal of Antimicrobial Chemotherapy
Study
P1106
Effects of combination antiretroviral therapy and nutritional rehabilitation on growth in children aged 6-36 months with severe acute malnutrition in IMPAACT protocol P1092
Citation
Blandina Theophil Mmbaga, James Samwel Ngocho, Camlin Tierney, Lauren Ziemba, Christina Reding, Frederic Bone, Sarah Bradford, Diane Costello, Renee Browning, John Moye, Tichaona Vhembo, Sharon Mambiya, Esnath Msowoya, Maxensia Owor, Philippa Musoke. Effects of combination antiretroviral therapy and nutritional rehabilitation on growth in children aged 6-36 months with severe acute malnutrition in IMPAACT protocol P1092. Journal of Paediatric Infectious Diseases. 2024 Aug 24; PMID: 38808862.Year
2024
Journal
Journal of Paediatric Infectious Diseases
Study
P1092
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-compar
Citation
Elizabeth D. Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E. Yin, Allison Agwu, Rohan Hazra, Conn Harrington, Rodica M. Van Solingen-Ristea, Cynthia C. McCoig, Adeola Adeyeye, Jared Kneebone, Vasiliki Chounta, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Ellen Chadwick, Allison Bearden, Herta Crauwels, Jenny Huang, Sarah Buisson, Ryan Milligan, Shawn Ward, Carolyn Bolton-Moore, Aditya H. Gaur, IMPAACT 2017 Team. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lancet HIV. 2024 Apr 01; 11(4):e222-e232. PMID: 38538161; PMCID: PMC11061207.Year
2024
Journal
Lancet HIV
Study
IMPAACT 2017
Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV
Citation
Lee Fairlie, Sean Brummel, Lauren Ziemba, Anne Coletti, Lameck Chinula, Roger Shapiro, Jeff Stringer, Grace Malonga, Renee Browning, Nahida Chakhtoura, Blandina Theophil Mmbaga, Tsungai P Mhembere, Ayotunde Omoz-Oarhe, Beatrice Nagaddya, Megeshinee Naidoo, Risa M Hoffman, Shahin Lockman, IMPAACT 2010/VESTED Study Team. Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV. Journal of the International AIDS Society. 2024 Oct 15; 97(2):150-155. PMID: 39742354; PMCID: PMC11684739.Year
2024
Journal
Journal of the International AIDS Society
Study
IMPAACT 2010
Safety and pharmacokinetics of lopinavir/ritonavir oral solution in preterm and term infants starting before 3 months of age
Citation
Adrie Bekker, Jincheng Yang, Jiajia Wang, Mark F. Cotton, Mae Cababasay, Lubbe Wiesner, Jack Moye, Renee Browning, Firdose L. Nakwa, Helena Rabie, Avy Violari, Mark Mirochnick, Tim. R Cressey, Edmund V. Capparelli. Safety and pharmacokinetics of lopinavir/ritonavir oral solution in preterm and term infants starting before 3 months of age. Pediatric Infectious Disease Journal. 2024 Apr 01; 43(4):355-360. PMID: 38190642; PMCID: PMC10939833.Year
2024
Journal
Pediatric Infectious Disease Journal
Study
P1106
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding st
Citation
Aditya H. Gaur, Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M. Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, John H. Moye, Barbara Heckman, Elizabeth D. Lowenthal, Shawn Ward, Ryan Milligan, Pearl Samson, Brookie M. Best, Conn M. Harrington, Susan L. Ford, Jenny Huang, Herta Crauwels, Kati Vandermeulen, Allison L. Agwu, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Pradthana Ounchanum, Jared L. Kneebone, Ellen Townley, Carolyn Bolton Moore, IMPAACT 2017 Team. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024 Apr 11; 11(4):e211-e221. doi: 10.1016/S2352-3018(23. PMID: 38538160; PMCID: PMC11213970.Year
2024
Journal
Lancet HIV
Study
IMPAACT 2017
Cognitive Behavioral Therapy Factors Related to Outcomes in Depression Among Youth with HIV
Citation
Betsy D. Kennard, Larry K. Brown, Kristin Baltrusaitis, Miriam Chernoff, Graham J. Emslie, Jessica Jones, Sarah Buisson, Jaime Deville, Megan Wilkins, Amber Bunch, Chivon McMullen Jackson, Christy Beneri, David E. Shapiro, IMPAACT 2002 Team. Cognitive Behavioral Therapy Factors Related to Outcomes in Depression Among Youth with HIV. Cognitive Therapy and Research. 2024 Aug 01; 48(4):781-790. PMID: 39664885; PMCID: PMC11634056.Year
2024
Journal
Cognitive Therapy and Research
Study
IMPAACT 2002